Large Employers, Insurers, PCMA Ask CMS To Retain Formulary Tools
This article was originally published in The Pink Sheet Daily
Executive Summary
A group of large employers, insurance companies and the Pharmaceutical Care Management Association has sent a letter to the Centers for Medicare & Medicaid Services arguing that the Medicare drug benefit should permit a wide range of cost effectiveness tools
You may also be interested in...
PCMA Launches Ad Campaign On Medicare Formulary Design
Print ad asks "Guess who's coming to dinner?" and features a sumo wrestler representing "the big drug companies." Inside-the-Beltway advertising campaign is designed to ensure that Medicare Rx formulary design permits current market practices, the PBM association says.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.